Demand in the U.S. heavy-duty first-fit markets softened ... And I feel confident about that being sustainable as we head out into 2025. And we'll be able to give a further update on our specific ...
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical ... current cash balance now projected to fund ...